A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Summary
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Description from CNBC.
Who is covering this
-
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Comments
Comments need JavaScript.